| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 4.0K | 2.3% |
| Total Income | 4.0K | 2.3% |
| Expenditure | 3.3K | 1.3% |
| PBT | 437.00 | 48.6% |
| Net Profit | 369.00 | 72.4% |
| OPM | 16.37% | 3.04pp |
| NPM | 9.27% | 3.77pp |
| EPS | 0.32 | 68.4% |
Teva Reports Strong Q1 2026 Results: Revenues ~$4.0 Billion, Up 2% YoY
03 May 2026 · 3 May, 6:18 pm
Summary
Teva Pharmaceutical Industries Ltd. reported a 2% increase in Q1 2026 revenues, reaching approximately $4.0 billion. This growth was primarily driven by the company's innovative portfolio, including AUSTEDO, AJOVY, and UZEDY. The company is maintaining its 2026 business outlook with projected revenues between $16.4 and $16.8 billion. Teva is also focusing on biosimilars as a key growth contributor and advancing its innovative late-stage pipeline.
Key Highlights
- 1
Teva's Q1 2026 revenues reached approximately $4.0 billion, reflecting a 2% increase year-over-year in U.S. dollars.
- 2
Global revenues for AUSTEDO® grew by 41% year-over-year in local currency, reaching $578 million.
- 3
AJOVY® global revenues increased by 35% year-over-year in local currency, totaling $196 million.
- 4
UZEDY® revenues increased by 62% year-over-year in local currency, reaching $63 million.
- 5
The company maintains its 2026 business outlook, projecting revenues between $16.4 and $16.8 billion.
- 6
Non-GAAP diluted EPS for Q1 2026 was $0.53.
- 7
Biosimilars are becoming an increasingly important growth contributor, alongside new product launches in generics.
Management Comments
Richard Francis
Our first quarter results are driven by strong growth in our key innovative products, continuing to shift Teva’s portfolio mix and support improvement in its financial profile. These results reflect disciplined execution of our Pivot to Growth strategy, and our focus remains unchanged: growing our innovative portfolio, improving margins and advancing key value-unlocking portfolio milestones expected during 2026 and beyond. In parallel, biosimilars are becoming an increasingly important growth contributor, alongside new product launches in generics, reinforcing the foundational importance of Teva's generic powerhouse.
Informational and educational content only. Not investment advice.